Drug Information

Drug (ID: DG01621) and It's Reported Resistant Information

• Name: AGI-6780
• Synonyms: AGI-6780; 1432660-47-3; AGI6780; N-cyclopropyl-4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido)benzenesulfonamide; AGI 6780; 1-[5-(Cyclopropylsulfamoyl)-2-Thiophen-3-Yl-Phenyl]-3-[3-(Trifluoromethyl)phenyl]urea; 1-[5-(CYCLOPROPYLSULFAMOYL)-2-(THIOPHEN-3-YL)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA; MLS006011046; CHEMBL3392845; SCHEMBL15702521; AOB2268; C21H18F3N3O3S2; DTXSID50744321; EX-A356; QCR-283; BDBM339679; HMS3653I21; HMS3744K17; HMS3865L13; BCP07383; 2198AH; FD5013; MFCD26097285; NSC781409; s7241; US10202339, Compound 124; ZINC95803998; AKOS024462890; CCG-269561; CS-1556; NSC-781409; SB19578; NCGC00347935-01; NCGC00347935-02; NCGC00347935-08; AS-55922; DA-35354; HY-15734; SMR004702838; FT-0764734; SW220033-1; Q27452174; S900006230; 1-[5-(cyclopropylsulfamoyl)-2-thiophen-3-ylphenyl]-3-[3-(trifluoromethyl)phenyl]urea; 3-(5-(cyclopropylsulfamoyl)-2-(thiophen-3-yl)phenyl)-1-(3-(trifluoromethyl)phenyl)urea; N-Cyclopropyl-3-[3-[3-(trifluoromethyl)phenyl]ureido]-4-(3-thienyl)benzenesulfonamide; 1K9; N-Cyclopropyl-4-(thiophen-3-yl)-3-({[3-(trifluoromethyl)phenyl]carbamoyl}amino)benzene-1-sulfonamide; N-Cyclopropyl-4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido)benzenesulfonamide
• Target: .; NOUNIPROTAC; [1]
• Formula: 6
• IsoSMILES: C1CC1NS(=O)(=O)C2=CC(=C(C=C2)C3=CSC=C3)NC(=O)NC4=CC=CC(=C4)C(F)(F)F
• InChI: InChI=1S/C21H18F3N3O3S2/c22-21(23,24)14-2-1-3-16(10-14)25-20(28)26-19-11-17(32(29,30)27-15-4-5-15)6-7-18(19)13-8-9-31-12-13/h1-3,6-12,15,27H,4-5H2,(H2,25,26,28)
• InChIKey: CCAWRGNYALGPQH-UHFFFAOYSA-N
• PubChem CID: 71299339

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Acute myeloid leukemia [ICD-11: 2A60]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Isocitrate dehydrogenase NADP 2 (IDH2) [1]

• Molecule Alteration: Missense mutation; p.R140Q (c.419G>A)
• Sensitive Disease: Acute myeloid leukemia [ICD-11: 2A60.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Blood; N.A.
• Mechanism Description: The missense mutation p.R140Q (c.419G>A) in gene IDH2 cause the sensitivity of AGI-6780 by aberration of the drug's therapeutic target

References

• Ref 1: Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationScience. 2013 May 3;340(6132):622-6. doi: 10.1126/science.1234769. Epub 2013 Apr 4.